This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caron, P. Articles by Susini, C. Search for Related Content PubMed PubMed Citation Articles by Caron, P. Articles by Susini, C.

Expression of Somatostatin Receptor SST4 in Human Placenta and Absence of Octreotide Effect on Human Placental Growth Hormone Concentration during Pregnancy¹

Service d’Endocrinologie et Maladies Métaboliques (P.C.) and INSERM U-151, Institut Louis Bugnard (L.B., J.-P.E., C.S.), IFR31, Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Service d’Endocrinologie (A.B.) et de Biochimie (A.I., G.H.), Centre Hospitalier Universitaire de Liège, Liège, Belgium

Address all correspondence and requests for reprints to: Dr. Philippe Caron, Service d’Endocrinologie et Maladies Métaboliques, CHU Rangueil, 1, avenue J. Poulhés, 31054 Toulouse Cedex 4, France.

In pregnancy, the human placenta GH acts as a growth-promoting hormone and appears to be the main stimulator of insulin-like growth factor I (IGF-I) secretion. In a woman with a TSH-secreting macroadenoma, successful treatment with the somatostatin analog octreotide was conducted during the first month and the second half of pregnancy without side-effects on placental and fetal development. As observed in normal pregnancy, both serum placental GH and IGF-I levels increased throughout pregnancy and dropped sharply after delivery. In placental membranes from both treated and healthy untreated patients, we demonstrated the presence of high affinity binding sites for somatostatin-14 (K_d, 4.6 and 5.3 nmol/L; binding capacity, 1.53 and 1.35 pmol/mg protein, respectively). These receptors displayed low affinity for octreotide (IC₅₀, 1.2–2 µmol/L), suggesting the presence of SST1 and/or SST4 receptors. We found that messenger ribonucleic acids of these two subtypes were expressed in both human placental tissue and purified human cytotrophoblast cells. Finally, the SST1-selective analog, des-AA^1,2,5[D-Trp⁸,IAmp⁹]S-14 had low affinity for placental somatostatin receptors. These results argue in favor of the presence of the SST4 subtype in human placenta. At the doses administered, octreotide did not bind to placental somatostatin receptors. Our results may explain the absence of changes in both human placental GH and IGF-I concentrations that we observed during octreotide treatment.

This article has been cited by other articles:

				R. Cozzi, R. Attanasio, and M. Barausse Pregnancy in acromegaly: a one-center experience. Eur. J. Endocrinol., August 1, 2006; 155(2): 279 - 284. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				S. Petersenn, A. C. Rasch, C. Bohnke, and H. M. Schulte Identification of an Upstream Pituitary-Active Promoter of Human Somatostatin Receptor Subtype 5 Endocrinology, July 1, 2002; 143(7): 2626 - 2634. [Abstract] [Full Text] [PDF]

				N. Benali, P. Cordelier, D. Calise, P. Pages, P. Rochaix, A. Nagy, J.-P. Esteve, P. M. Pour, A. V. Schally, N. Vaysse, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238 PNAS, August 1, 2000; 97(16): 9180 - 9185. [Abstract] [Full Text] [PDF]